Panel 1: Key Recommendations for Managing Patients With Rheumatic Diseases During The COVID-19 Epidemic


Potential risk factors for SARS-CoV-2 infection in patients with rheumatic diseases


Medication for patients with rheumatic diseases #



Patients with RD and fever*

personal protection provisions if temperature continues over 38°C

# Concerning glucocorticoids, immunosuppressants, csDAMRDs, bDMARDs and JAK inhibitors, the balance of safety and efficacy in viral infection as well as pulmonary inflammation remains unclear.